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Abstract
Objective: To study the long-term efficacy and safety of the cholesterol synthesis inhibitor, simvastatin, in the 
treatment of familial hypercholesterolaemia.
Methods: This is an open long-term follow-up of patients treated for 5 years or more in the Nijmegen University 
lipid clinic. Forty-four patients with heterozygous familial hypercholesterolaemia (mean baseline serum cholesterol 
level 11.5 mmol/1) were treated with simvastatin alone (monotherapy group) in doses ranging from 20 to 80 mg/day, 
or in combination with other lipid-lowering agents (combination-therapy group).
Results: Over the intervention period of 6 years the mean overall reduction of the serum cholesterol level was 
37.8% for the total group, 37.7% for the monotherapy group and 42.6% for the combination-therapy group. The 
reduction of the low-density lipoprotein (LDL)-cholesterol in the three groups was 45.0, 44.6 and 50.3%, respec­
tively. The serum triglyceride concentration was reduced by 14.0, 20.5 and 12.5%, respectively. The increase in the 
high-density lipoprotein (HDL)-cholesterol level was 14.4, 16.2 and 14.0%, respectively. One patient died from a 
myocardial infarction and 2 patients had a non-fatal cardiac event. Two patients stopped taking medication due to 
side-effects (dizziness and insomnia). Biochemical adverse effects were confined to elevations of the alanine 
aminotransferase level and the creatine phosphokinase level and did not lead to discontinuation of therapy.
Conclusions: Simvastatin proves to be a safe and effective lipid-lowering drug during long-term treatment.
Keywords: HMG-CoA reductase inhibitors; Cholesterol; Hyperlipidaemia
1. Introduction
A high serum cholesterol level is a major risk 
factor for the development of coronary heart 
disease [1], Intervention studies with diet and
* Corresponding author. Tel. ( + 31-80) 614782; Fax ( + 31- 
80) 541734.
drugs have shown that lowering the concentra­
tions of total and low-density-lipoprotein (LDL) 
cholesterol in the blood can reduce the risk of 
coronary heart disease and arrest the progression 
of atherosclerotic lesions [2,3]. Patients with fa­
milial hypercholesterolaemia (FH) are especially 
at high risk of premature atherosclerosis [4]. Sub­
jects heterozygous for this disorder have only half 
the normal amount of high-affinity receptors for
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LDL on cell membranes, and LDL levels are 2-3 
times elevated compared to normal subjects [5]. 
Cholesterol-lowering diets have only a limited 
effect, which makes treatment with (a combina­
tion of) drugs necessary in these patients. A  new 
class of drugs, the cholesterol-synthesis inhibitors, 
has been used for several years now. These drugs 
inhibit competitively 3-hydroxy-3“methylglutaryl 
coenzyme A (HMG-CoA) reductase, the key en­
zyme in the biosynthesis of cholesterol. Short-term 
clinical studies have shown that the cholesterol 
level can be reduced by means of these drugs by
30-40% on average, with a maximum reduction 
of 60% of the baseline value, without serious 
side-effects [6-14]. Furthermore, combination 
with bile-acid-binding resins can reduce serum 
cholesterol even further [13].
Simvastatin is the most potent drug in this 
class [11,14], After oral ingestion simvastatin is 
rapidly absorbed by the intestine, reaching its 
peak plasma concentration after 2 h in healthy 
volunteers. Approximately 4 h after ingestion the 
plasma concentrations have fallen by 50%, The 
main route of excretion is through the biliary 
tract [for review, see Ref. 15]. Earlier studies of 
the long-term effects of simvastatin are confined 
to studies with a mean follow-up of 1.5 years [14]. 
Simvastatin was introduced as the first drug of 
this class in our lipid clinic in 1985 for the treat­
ment of patients with familial hypercholestero- 
laemia. The long-term results of this treatment 
with a mean duration of 6 years in 55 patients will 
be discussed.
2. Patients and methods
Patients
In this retrospective study 55 patients with 
heterozygous familial hypercholesterolaemia were 
recruited from our out-patient lipid clinic and 
were treated in the period from 1985 to 1994. 
The diagnosis of FH was based on patient and 
family history, lipid profile in the patient and 
first-degree relatives and the presence of tendon 
xanthomata. This group consisted of well-char­
acterized FH patients who had participated in 
earlier short-term studies [6,7]. Lipid-lowering
therapy with simvastatin was started initially in all 
patients. During treatment 8 patients stopped 
attending the research program and came under 
medical supervision elsewhere, 2 patients stopped 
treatment due to side-effects and 1 patient died 
of myocardial infarction during treatment. For at 
least 5 years the remaining 44 patients were 
treated continuously with simvastatin as mono­
therapy, or in combination with another lipid- 
lowering drug. All patients were on a regular 
cholesterol-lowering diet (cholesterol < 300 mg/ 
day), containing 30% of energy as fat and a 1:1 
ratio of saturated and unsaturated fatty acids; 
they all discontinued any other lipid-lowering drug 
at least 6 weeks before the start of treatment with 
simvastatin.
The population consisted of 44 patients, 
equally divided into 22 men and 22 women. The 
average age in this population at the start of the 
study was 44 ± 12 years; the men were on average 
11 years younger than the women (Table 1). Out 
of the 44 patients 14 were overweight (body mass 
index > 25.0 kg/m 2). Additional risk factors like 
hypertension and smoking were found in 5 (11%) 
and 16 (36%) patients, respectively. One or more 
vascular complications were diagnosed in 23 pa­
tients by means of patient history and physical 
examination: 16 of 44 (36%) patients had angina 
pectoris, 4 of 44 (9%) had suffered from a my­
ocardial infarction, 7 of 44 (16%) had peripheral 
vascular disease (murmur, claudication) and 3 of 
44 (7%) had a history of stroke.
Table 1
Demographic characteristics of the study population at base­






Age (years) 39 ±12 50 +9 44 ± 12
BMI (kg/m2) 24.4 ± 2.5 25.4 ±4.0 24.9± 3.4
Overweight 6 (27%) 8 (36%) 14 (32%)
Cigarette smoking 6 (27%) 10 (45%) 16 (36%)
Hypertension 2 (9%) 3 (14%) 5 (11%)
PVD 3 (14%) 4 (18%) 7 (16%)
Stroke 3 (14%) 0 3 (7%)
CAD 11 (50%) 9 (41%) 20 (45%)
Results represent mean ± SD; BMI = body mass index; PVD 
= peripheral vascular disease; CAD = coronary artery dis­
ease.
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These patients made up the total study popu­
lation. During treatment of these patients with 
simvastatin other lipid-lowering drugs were used 
concomitantly in 30 patients. To be able to de­
duce the effect of treatment with simvastatin, two 
groups were selected: (a) patients who had been 
treated with simvastatin as monotherapy for at 
least 80% of the period of treatment (n = 17), 
and (b) patients who had been treated with sim­
vastatin and another lipid-lowering drug for at 
least 80% of the period of treatment (n = 15). As 
additional lipid-lowering drug, cholestyramine was 
administered in 7 patients, colestipol in 6 patients 
and gemfibrozil in 2 patients of the second group. 
The remaining patients did not meet the duration 
criteria of monotherapy or combination therapy. 
Treatment with simvastatin varied from 20, 40 to 
80 mg/ day in the evening, until a maximum 
cholesterol-lowering effect had been achieved (2 
patients received 20 mg/day, 38 received 40 mg/ 
day and 4 patients received 80 mg/ day). Initially 
all patients were examined every 3 months. Sub­
sequently, the intervals were extended from 3 to 6 
months. At every examination blood was taken 
for determination of serum lipids, creatine phos- 
phokinase (CK) and alanine aminotransferase 
(ALAT) levels.
Analytical methods
Serum cholesterol and triglycerides were de­
termined by enzymatic methods. The high-density 
lipoprotein (HDL)-cholesterol was determined
after precipitation of other lipoproteins with 
polyethylene glycol 6000 [16]. LDL-cholesterol 
was calculated by subtraction [17].
Statistical analysis
Statistical analyses were performed using the 
“SPSS”-software package for personal comput­
ers. For analyses of trends, an analysis of variance 
(ANOVA) was used, corrected for repeated mea­
surements, and followed by a Mann-Whitney U- 
test. A two-sided ^p-value of less than 0.05 was 
considered to be significant. Unless indicated 
elsewhere, values are expressed as mean ± SD.
3. Results
Lipids
The baseline serum cholesterol level of the 
total population of 44 patients was 11.46 ± 1.68 
mmol/1 (Table 2). During treatment with simvas­
tatin a reduction in serum cholesterol level of 
37.6% was assessed after 0.5 years. After 6 years 
the decrease in relation to the baseline value was 
38.3%. There were no significant differences in 
the intervening years. A similar pattern was noted 
for the LDL-cholesterol level, which decreased, 
compared to the baseline value, by 43.3% after
0.5 years and 44.4% after 6 years. The serum 
triglycerides also decreased during treatment by 
an average of 14.0% over the 6-year period (Ta­
ble 2). During simvastatin treatment the HDL-
Table 2
Serum total cholesterol (Tot.cholX low-density-lipoprotein cholesterol (LDL-C), high-density-lipoprotein cholesterol (HDL-C) and 
triglycerides (TG) in patients with heterozygous familial hypercholesterolaemia, treated > 5 years with simvastatin alone or in 
combination with another lipid-lowering drug
Tot. chol. % LDL-C % HDL-C % TG % n
Baseline 11.46(1.68) • 9,69(1.64) 1.05(0.26) 1.74(0.69) 44
0.5 year 7.10(1.24) -37.6 * 5.42(1.19) -43.3 * 1,15(0.27) + 11.9 * 1.41(0.76) -18.3 * 44
1.0 year 6.98(1.20) -38.6 5.17(1.17) -46.4 1.18(0.32) +13.6 1.45(0.75) -14.0 44
2.0 years 6.93(1.13) -39.1 5.16(1.08) -46.5 1.20(0.36) +14.8 1.42(0.62) -15.0 43
3.0 years 7.11(1.01) -37.0 5.33(1.05) -44.2 1.15(0.32) - 10.2 1.56(0.92) - 11.0 44
4.0 years 6.93(0,96) -38.5 5.13(1.01) -46.0 1.21(0.29) + 13.7 1.42(0.68) -15.5 41
5.0 years 7.08(1.03) -37.4 5.25(1.04) -44.9 1.22(0.37) + 16.7 1.51(0.76) -9.9 43
6.0 years 7.01(1.18) -38.3 5.31(1.07) -44.4 1.14(0.38) + 9.9 1.35(0.77) -21.9 34
Mean -37.8 -45.0 + 14.4 -14.0
Data represent mean (±SD) in mmol/1, n = number of patients. 
* p < 0.05 vs. baseline (ANOVA, Mann-Whitney U-test).
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Table 3
Serum total cholesterol (Tot.choL), low-density-lipoprotein cholesterol (LDL-C), high-density-lipoprotein cholesterol (HDL-C) and 
triglycerides (TG) in patients with heterozygous familial hypercholesterolaemia, treated > 5 years with simvastatin as monotherapy
Tot.choL % LDL-C % HDL-C % TG % n
Baseline 11.07(1.51) 9,29(1.51) 1.10(0.36) 1,53(0.61) 17
0.5 year 6.72(1.29) -38.4 * 5.11(1.27) — 43.8 * 1.25(0.28) + 15.8 * 1.14(0.60) -26.3 * 17
1.0 year 6.68(0.79) -39.2 4.84(0.80) -47.5 1.26(0.28) + 15.7 1.22(0.43) ' -17.0 17
2.0 years 6.93(1.20) -37.5 5.16(1.19) -44.7 1.29(0.32) + 17.5 1.19(0.45) -19.8 16
3.0 years 6.81(1.13) — 38.1 5.12(1.24) -44.8 1.19(0.32) + 15.0 1.23(0.58) -16.8 17
4.0 years 6.74(1.14) -37.5 5.00(1.17) -44.5 1.27(0.25) +13,8 1.13(0.46) — 22,8 16
5.0 years 6.84(0.87) -37.4 5.12(0.93) -43.9 1.22(0.28) + 11.7 1.18(0.61) -23.0 17
6.0 years 6.91(1.09) -35.1 5.12(1.01) -42.1 1.27(0.36) + 17.0 1.22(0.82) — 20.6 13
Mean -37.7 -44.6 +16.2 -20.5
Data represent mean (±SD) in mmol/1, n — number of patients. 
p < 0.05 vs. baseline (ANOVA, Mann-Whitney U-test).
cholesterol level was constantly significantly ele­
vated with values varying from 9.9% after 6,0 
years to 16.7% after 5 years, with an overall mean 
of 14.4% (Table 2).
Before treatment with simvastatin, the serum 
cholesterol level was severely increased in all 
patients (vaiying from 8.24 to 14.78 mmol/1). 
After 5 years of treatment, 25% of the patients 
had a cholesterol level of less than 6.4 mmol/1, 
50% between 6.4 and 7.8 mmol/1, and 25% of 
the patients had a serum cholesterol level which 
was still above 7.4 mmol/1.
From 17 patients who were on monotherapy 
with simvastatin, the baseline cholesterol level 
was 11.07 ± 1.51 mmol/1 and the LDL-cholesterol 
level 9.29 + 1.51 mmol/1 (Table 3). The daily 
dose of simvastatin ranged from 20, 40 to 80 mg
(1 patient received 20 mg/day, 14 received 40 
mg/day and 2 patients received 80 mg/day). 
The baseline values of the total cholesterol and 
the LDL-cholesterol of 15 patients who received 
combined therapy were higher than in the 
monotherapy group (12.31 ± 1.71 mmol/1 and 
10.55 ± 1.71 mmol/1, respectively) (Table 4). The 
daily dose of simvastatin was 40 and 80 mg (14 
patients received 40 mg/day and 1 patient re­
ceived 80 mg/ day).
During treatment a sustained reduction in 
serum cholesterol levels was observed. During the 
course of time there was no change in choles- 
terol-lowering effect (Figs. 1 and 2). After 6 years 
of treatment the serum total cholesterol level 
declined by 35.3% in the patients of the 
monotherapy group and by 43.6% in the patients
Table 4
Serum total cholesterol (Tot.choL), low-density-lipoprotein cholesterol (LDL-C), high-density-lipoprotein cholesterol (HDL-C) and 
triglycerides (TG) in patients with heterozygous familial hypercholesterolaemia, treated > 5 years with simvastatin in combination 
with another lipid-lowering drug
Tot. chol. % LDL-C % HDL-C % TG % n
Baseline 12.31(1.71) 10.55(1.71) 0.97(0.20 2.00(0.79) 15
0.5 year 7.85(1.22) -36.2 * 6.08(1.17) -42.4 * L 10(0.21) + 13.4 * 1.72(0.91) -14.0 * 15
1.0 year 7.03(1.45) — 42.9 5.22(1.48) -50.5 1.11(0.31) +14.4 1.72(0.98) -14.0 15
2.0 years 6.57(1.06) -46.6 4.83(0.91) -54.2 1.10(0.28) + 13.4 1.58(0.62) - 21.0 15
3.0 years 6.94(0.68) -43.6 5.08(0.81) -51.9 1.13(0.29) + 16.5 1.79(1.14) -10.5 15
4.0 years 7.06(0.71) -42.7 5.20(0.81) -50.7 1.16(0.24) +19.6 1.66(0.69) -17.0 14
5.0 years 7.08(1.13) -42.5 5.16(1.16) -5.11 1.16(0.29) + 19.6 1.81(0.74) -9.5 15
6.0 years 6.94(1.33) -43.6 5.30(1.11) -49.8 0.96(0.14) - 1.0 1.66(0.80) -17.0 12
Mean -42.6 -50.3 +14.0 -12.5
Data represent mean (±SD) in mmol/1, n — number of patients. 
* p < 0.05 vs. baseline (ANOVA, Mann-Whitney U-test).
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Simvastatin monotherapy
(n-17)
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years of treatment
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Fig. 1. Mean changes in lipid levels over time in response to 
long-term simvastatin monotherapy (20-80 mg/day). Top, 
absolute values; bottom, percent change.
from the combination-therapy group. With re­
spect to the LDL-cholesterol level, these percent­
ages were 42.1 and 49.8, respectively (Tables 3 
and 4), In terms of percentages the decrease in 
serum cholesterol and LDL-cholesterol levels was 
significantly greater in the combination-therapy 
group. In the monotherapy group the triglyceride 
level had significantly declined by a mean of 
20.5% over the 6-year period; in the combina- 
tion-therapy group this decline was significantly 
lower with an average of 12.5% (Tables 3 and 4). 
In these two groups a mean increase in HDL- 
cholesterol was observed of 16.2 and 14.0%, re­
spectively, over the 6-year period.
Clinical events and side-effects
One patient of this group died at age 67 from 
a myocardial infarction; he was known to have 
had severe coronary atherosclerosis and had been
using simvastatin for 2 years. Another patient 
suffered from a myocardial infarction at age 46, 
and a third one developed angina pectoris at age 
43. Both patients used simvastatin for 1 year.
Two patients stopped taking simvastatin medi­
cation due to the occurrence of side-effects. One 
subject, who was on simvastatin for 3 years with­
out problems, stopped taking the drug due to 
complaints of dizziness, which disappeared after 
discontinuation and recurred after rechallenge. 
The other patient complained of insomnia during 
therapy after several months.
During treatment an elevation of the ALAT 
concentration occurred in 13 of the total of 44 
patients (30%). At one point the ALAT level 
exceeded the upper level of normal (<30  U /l) 
by more than 100% in 2 patients. In one patient 
an increase of more than 200% of the upper limit 
of normal was measured in the ALAT level. In 11
Combination therapy
(n-15)
years of treatm ent
- Q  —  TC  - O -  LD Lc H D L c  - A -  TG
Fig. 2. Mean changes in lipid levels over time in response to 
long-term combination therapy. Top, absolute values; bottom, 
percent change.
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of the 13 patients the ALAT level returned to 
normal, although simvastatin treatment was con­
tinued. A  consistently elevated ALAT level, be­
tween 30 and 60 U /l, occurred in 2 patients. The 
elevation of the ALAT level of one of these 2 
patients may have been caused by excessive alco­
hol consumption. Simvastatin treatment was not 
interrupted in either of them,
A  rise in the CK level above the upper limit of 
normal (<  100 U /I) was measured one or more 
times in 19 patients (43%). A  CK level between 
100 and 200 U /l was measured in 8 patients, 
between 200 and 300 U / l in 9 patients, and 2 
patients once had a CK level between 400 and 
500 U /l. These levels were not accompanied by 
muscle complaints. They were usually observed 
after considerable physical exercise and did not 
recur at the next examination.
4. Discussion
In this report we present our experience with 
simvastatin in the treatment of patients with fa­
milial hypercholesterolaemia with a follow-up of 
more than 5 years. The group of patients repre­
sented a highly motivated category of subjects 
with a severely increased risk of coronary events 
(45% had already had coronary disease at entry 
to the study, a mean baseline cholesterol level of
11.5 mmol/1, and a family history of coronary 
disease), which may help to explain the markedly 
consistent and strong hypolipidaemic effect of 
treatment. During use of the drug the serum total 
cholesterol level fell by approximately 38%. The 
cholesterol-lowering effects especially concerned 
the LDL-cholesterol level, which decreased by 
approximately 45%. These decreases are of equal 
size compared to decreases observed earlier 
shortly after initiation of the therapy [6,7]. In 
spite of this considerable lipid-lowering effect of 
simvastatin, only 25% of the study population 
reached a total cholesterol level of less than 6.4 
mmol/1, as a result of the very high cholesterol 
baseline values in these patients with heterozy­
gous FH. This makes the administration of a 
combination of drugs with a different mode of 
action mostly necessary in this population.
During monotherapy the changes in terms of 
percentages were not related to the baseline val­
ues. There was a decrease in the triglyceride level 
and a rise in the HDL-cholesterol level, also 
comparable to those observed in short-term stud­
ies [6,7]. In patients who still had an elevated 
cholesterol level during monotherapy with sim­
vastatin, in spite of a considerable decrease in 
terms of percentages, the addition of a bile-acid- 
binding resin resulted in a further decrease in 
total cholesterol of 5% of the baseline value, but 
a less marked decrease in serum triglycerides.
During the course of the follow-up only 3 
(6.8%) patients suffered from a cardiac event. 
This figure is comparable to the number of events 
found in a larger study with lovastatin [10]. Al­
though this event rate may seem low considering 
the high-risk nature of the study population, our 
study cannot provide information on reduction of 
coronary risk, because there was no parallel con­
trol group. Several angiographic investigations 
with surrogate endpoints show less progression of 
coronary atherosclerosis in actively treated pa­
tients with an even lower risk, including the re­
cently reported Multicentre Anti-Atheroma 
Study, which also applied simvastatin (18). Data 
from the PLAC-II study suggested a reduction of 
coronary events after 3 years of treatment with 
pravastatin, and showed a slowing of the progres­
sion of atherosclerosis in the carotid artery [19]. 
The results of several large trials of the HMG- 
CoA reductase inhibitors have to be awaited con­
sidering the possibly greater prevention potential 
in comparison to older drugs like resins, fibrates 
and niacin.
The effects of cholesterol synthesis inhibitors 
are not limited to patients with familial hyperc­
holesterolaemia. These drugs are also very effec­
tive with other forms of hypercholesterolaemia, 
including familial combined hyperlipidaemia, fa­
milial dysbetalipoproteinaemia, and secondary 
forms of hypercholesterolaemia [20,21],
The inclusion of a control group would have 
made the interpretation of adverse events easier, 
but this was of course impossible in this group of 
FH patients in such a lengthy study. Subjective 
side-effects, however, hardly occurred and led to 
discontinuation of treatment in just 2 patients. In
R.E. Knops et al. /Netherlands Journal of Medicine 46 (1995) 171-178 111
general, the cholesterol synthesis inhibitors are 
well tolerated. Subjective adverse experiences re­
ported are limited to abdominal pain, flatulence, 
constipation, and headache, each occurring in 
1-3% of patients, and they appear not to differ 
from those caused by the most widely used drugs 
(lovastatin, simvastatin, pravastatin) [for review, 
see Ref, 21].
Concern about possible induction of lens opac­
ities in the early years of use of cholesterol syn­
thesis inhibitors has not been realized, and regu­
lar ophthalmological examinations are no longer 
required [14,21].
A small percentage of patients complain about 
central nervous system effects, such as headache 
and insomnia, during treatment with cholesterol 
synthesis inhibitors [22,23]. A  causal relationship 
between the cholesterol synthesis inhibitors and 
these adverse effects remains unclear because of 
the high prevalence of these symptoms in un­
treated patients. The EXCEL study of lovastatin 
including over 8000 patients showed no signifi­
cant excess of headache (2.6-3.2% in the active- 
drug-treated patients) over that in the placebo
group (2.7%) [22].
Transaminase elevations have been reported 
in virtually all clinical trials of this class of drugs. 
In EXCEL, the percentage of patients with an 
elevation of transaminases above 3 times the up­
per limit of normal increased dose-dependently 
from 0.1% on placebo and 20 mg/ day to 1*5% on 
80 mg/day [22], In the 1.5-year follow-up study 
of simvastatin in 2400 patients taking 20-40 mg/ 
day, 1% developed increases of transaminases of 
more than 3 times the upper normal level [14]. 
Currently, we recommend that liver function tests 
be monitored every 6 weeks in the first 6 months 
and periodically thereafter (2 times per year), and 
to stop the drug if transaminases increase above 3 
times the upper limit of normal [21].
CK elevations can result from exercise or mi­
nor muscle trauma and are often not drug-re­
lated; in EXCEL, 29-35% of patients on active 
drug had CK elevations at some time during the 
study, but this was also present in 29% of pa­
tients on placebo [22]. Muscle symptoms devel­
oped in 7-9% of patients both on placebo and on 
effective drug. Frank myopathy was observed in 5
out of 6582 patients receiving active drug (0.08%), 
but no rhabdomyolysis developed. In the 1.5-year 
study of simvastatin, myopathy was observed in 
0.08% of 2400 patients [14]. Rhabdomyolysis has 
been reported with HMG-CoA reductase in­
hibitors used in combination with gemfibrozil, 
cyclosporin, erythromycin or nicotinic acid [21]. 
Currently, it appears not to be useful to monitor 
CK levels in order to reveal myopathy; patients 
should be instructed to contact their physician 
when muscle symptoms occur.
In conclusion, the efficacy of simvastatin was 
fully maintained during this long-term follow-up, 
with good tolerability and a low adverse event 
rate. Undoubtedly, this class of drugs will prove 
to have a great impact on both total and cardio­
vascular morbidity and mortality in this high-risk 
patient group.
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